🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Charles River Laboratories International, Inc. CRL SPX

Healthcare · Diagnostics & Research · United States
https://www.criver.com
Company Profile ↓
$228.22
+44.41% 1Y
Mkt Cap$10.99B
P/E-61.35
P/B3.79
52W High$233.60
52W Low$145.57
Book Value$61.05
EPS (TTM)$-3.72

Company Overview

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Why Investors Should Care

Healthy Margins

Operating margin of 15.9% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $4.02B (-0.9% YoY); net profit $-144.34M.
  • Trailing 12 Months Year-on-year growth — revenue +1.2%, earnings -750.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 6.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:6.88%
1 Year:1.20%

Compounded Profit Growth

5 Years:-
1 Year:-750.08%

Stock Price Performance

1 Year:+44.41%
6 Months:+4.30%
3 Months:+27.28%
1 Month:+21.71%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 94% of range
$145.57 $233.60
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross8d ago
  • RSI (14)66.19 · Neutral
Price Performance
1M+21.71%
3M+27.28%
6M+4.30%
1Y+44.41%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-61.35
Industry PE
25.88
Forward P/E
18.51
PEG Ratio
0.12
Book Value
$61.05
Price to Book
3.79
P/S
2.77
EV/EBITDA
15.72
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
6.88%
Profit 5Y
-
Revenue (YoY)
1.20%
Earnings (YoY)
-750.08%

Profitability & Returns

ROCE
0.42%
ROE
-5.87%
ROA
4.26%
Profit Margin
-4.58%
Op Margin
15.92%
Gross Margin
34.46%
EPS (Latest Qtr)
$-0.30
EPS (TTM)
$-3.72

Balance Sheet & Liquidity

Debt/Equity
1.03
Quick Ratio
0.82
Current Ratio
1.36
Debt
$3.06B
Total Assets
$7.73B
Current Assets
$1.49B
Working Capital
$326.73M

Ownership

Promoter Holding
0.64%
Chg in Prom Hold
-
FII / Inst Holding
123.35%
Chg in FII Hold
0.05%

Financial Snapshot

Enterprise Value
$10.99B
Total Revenue (TTM)
$4.03B
EBITDA
$889.62M
Free Cash Flow
$510.02M
Operating Cash Flow
$607.03M
Shares Outstanding
48.17M
Gross Margin
34.46%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CRL Charles River Laboratories International, Inc. SPX 228.22 -61.35 $10.99B 0.00% 0.42% -5.87% 6.88% -
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Apr 2017Jul 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Apr 2023Jul 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue --------445.76M469.13M464.23M478.48M493.97M585.30M585.29M601.53M604.57M657.57M667.95M691.14M707.06M682.58M743.30M790.99M824.57M914.61M895.94M913.93M973.13M989.16M1.03B1.06B1.03B1.01B1.03B1.01B984.17M1.03B1.00B995.83M
Gross Profit 119.66M132.78M138.07M140.57M140.77M169.75M156.27M179.88M171.35M185.32M176.85M167.39M181.47M215.98M216.20M226.42M211.78M238.10M246.12M262.31M252.06M232.24M289.27M299.97M----------------
Operating Income 43.01M55.73M55.44M52.27M51.47M58.06M58.80M69.09M69.71M81.69M74.06M62.83M67.83M76.71M84.36M102.48M69.79M79.77M92.80M108.79M94.28M76.77M132.75M128.93M123.70M137.55M155.80M148.78M187.41M150.98M167.89M164.94M151.50M125.98M151.65M117.41M74.67M100.13M133.80M119.90M
Net Income 31.54M48.51M37.38M-37.14M35.21M37.73M-46.78M53.95M52.47M-29.85M52.63M53.71M60.37M59.66M55.13M43.73M72.81M80.35M50.77M67.44M102.91M143.19M61.53M88.45M103.43M93.02M109.32M96.47M103.13M97.02M87.39M72.96M94.08M69.66M25.47M52.33M54.42M-14.84M
Diluted EPS 0.661.020.790.670.780.730.790.930.971.121.08-0.631.081.101.221.211.110.881.461.611.021.342.032.811.201.722.011.812.131.882.011.891.691.301.741.330.501.061.10-0.30

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.30B1.17B1.13B1.14B1.13B1.17B1.30B1.36B1.68B1.86B2.27B2.62B2.92B3.54B3.98B4.13B4.05B4.02B
Operating Income -451.84M169.61M-298.51M174.31M165.76M151.40M177.67M206.45M237.55M288.28M331.38M351.15M432.73M589.86M650.98M617.26M227.35M25.16M
Net Income -524.50M114.44M-336.67M109.57M97.30M102.83M126.70M149.31M154.76M123.36M226.37M252.02M364.30M390.98M486.23M474.62M22.20M-144.34M
Diluted EPS -7.801.74-5.382.142.012.122.663.133.232.544.625.077.207.609.489.220.20-2.91

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --2.20B1.73B1.56B1.59B1.63B1.87B2.07B2.71B2.93B3.86B4.69B5.49B-7.60B8.20B7.53B7.14B
Current Assets ---------------1.44B1.61B1.40B1.45B
Cash & Equivalents 225.45M243.59M182.57M179.16M68.91M109.69M155.93M160.02M117.95M117.63M163.79M195.44M238.01M228.42M-233.91M276.77M194.61M213.77M
Inventory ---------------255.81M380.26M278.54M299.10M
Receivables ---------------559.41M578.08M527.71M518.73M
Total Liabilities --830.27M1.04B1.03B983.14M968.10M1.17B1.30B1.86B1.87B2.52B3.03B3.35B-4.58B4.54B4.02B3.92B
Current Liabilities --249.77M259.78M216.80M342.25M247.03M294.69M311.76M429.59M463.50M558.22M710.18M839.75M-1.09B1.06B994.10M1.12B
Long Term Debt ---670.22M703.17M527.08M641.81M722.04M821.04M1.19B1.09B1.63B---2.71B2.65B2.21B2.11B
Total Debt ---------------3.10B3.07B2.72B2.57B
Total Equity 1.91B1.24B1.38B687.42M525.58M600.80M640.98M672.20M733.07M836.77M1.05B1.32B1.63B2.11B-2.98B3.60B3.46B3.16B
Shares Outstanding ---------------50.94M51.34M51.14M49.22M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --------316.90M318.07M441.14M480.94M546.58M-619.64M683.90M734.58M737.65M
Investing Cash Flow ---------692.67M-72.59M-955.00M-681.50M-601.54M--607.92M-563.15M-245.09M-209.32M
Financing Cash Flow --------380.76M-208.48M558.06M231.94M47.25M--42.40M-85.52M-550.93M-536.73M
Capital Expenditure ---------------324.73M-318.53M-232.97M-219.15M
Free Cash Flow --------------294.91M365.37M501.61M518.49M
Net Change in Cash ---------------30.68M35.22M-61.44M-8.40M
Share Buybacks 115.06M45.90M356.53M283.80M64.19M165.93M122.02M117.48M12.27M106.91M13.85M18.09M23.98M40.71M38.65M24.16M119.17M360.67M

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------------
Operating Margin % -34.9%14.5%-26.3%15.3%14.7%13.0%13.7%15.1%14.1%15.5%14.6%13.4%14.8%16.7%16.4%14.9%5.6%0.6%
Net Margin % -40.5%9.8%-29.7%9.6%8.6%8.8%9.8%11.0%9.2%6.6%10.0%9.6%12.5%11.0%12.2%11.5%0.5%-3.6%
ROE % -42.2%8.3%-49.0%20.8%16.2%16.0%18.8%20.4%18.5%11.8%17.2%15.4%17.2%-16.3%13.2%0.6%-4.6%
ROCE % -8.7%-20.3%13.0%13.3%10.9%11.3%11.8%10.4%11.7%10.0%8.8%9.3%-10.0%8.6%3.5%0.4%

Shareholding Pattern

Insiders
0.64%
Institutions
123.35%
Public Float
124.14%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.01% 3.86M $892.26M
2 FMR, LLC 7.18% 3.46M $799.12M
3 Vanguard Capital Management LLC 6.65% 3.20M $740.38M
4 Invesco Ltd. 4.98% 2.40M $554.27M
5 Vanguard Portfolio Management LLC 4.76% 2.29M $530.55M
6 Harris Associates L.P. 4.47% 2.15M $497.86M
7 Allspring Global Investments Holdings, LLC 4.14% 1.99M $460.87M
8 State Street Corporation 3.89% 1.87M $433.20M
9 Dimensional Fund Advisors LP 3.43% 1.65M $382.07M
10 Wellington Management Group, LLP 3.38% 1.63M $376.73M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CRL

Google News Wed, 15 Jul 2026

Charles River investors will get Q2 results before market open Aug. 5 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZjEzd19VS2RpQlFKM203MUdpTUIzQVVEYVl0M1E1bjU2eWhXRERhZUhUU1h2bkl5eWRYZjAweUZJV3ZFdHItSFptWmZnOGFuMGdIOWFDemVhTEJKS0ZpcExoU3V2Tjh1NzJfelBMSHVFMm93eTBpVC1fQWtfT0hZNkZIUmxYbXluNzNqb2…

Google News Wed, 01 Jul 2026

Is This the Right Time to Hold CRL Stock in Your Portfolio? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPX2gwalgwZVNfZUtIeExuX2FSY3NmY1UyTnpsb04wbVh4UXdYcWd0R285Znd2U2RpWXhLaXNyMDNsdV9jY0M4ZURWYUdlUG9Db25fRXBSSEpRZ19zUjF1WTc3VUVuYTVEaXdiQVJNLTh3ZlpiZUxQV01VSktuRlVLeTJFczBYdHZHc2FaMX…

Google News Fri, 10 Jul 2026

FDA Pauses Release of New CRL’s Following Citizen’s Petition - Pharmaceutical Executive

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQX05vYWpzX2xuaGNIdVlWMzVnVlVHaWU2eGRra1JLLVJ4R2pxNUx4QmRjbXJMUnpBdkJkWWtVNXBXTGdMZUdLM0FtY0FheW5jYlM5MXBwOTdDNGRzbjhtaWlhUnBXZS1LbUFMaE4yQy11Y05Od0ZLYWFhd3FFeXpkOFFlS244eGgxc2d3Mw…

Google News ue, 14 Jul 2026

Canaccord reiterates Achieve Life Sciences stock rating on CRL review - Investing.com

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPMGExaUdRZFItZEh5VUJFN0p2c09BZUJ3bHBJM0ZTaW44dVIyek5Rd2dYT3NtX1JTWGI4MjVUWUo1a2Y4QWVRRjZ5aTJjUF83cEplQjRtcFBWdDVrMURVNHVSYUpRS3BzOGcyTEhPcjE5YlBzMTRhOF9nVXowQUxRbVMxVFNNS0V5eU5VM0…

Google News Sun, 12 Jul 2026

Charles River Laboratories International (CRL) Expands AI Pathology Platform, Is The Valuation Upside Already Priced In? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxObXB5a0xrYkRoaGtiQV9ka3BEOGkzNE80c3N4ZlEwanctZk45bVBsTy1tX2lFU2FJblUtREhFQXE1R2pFY292YnRUZ0ZzOFlZQXVLQkNfclFnT1BBV0pNV3dSQ2toRG13RGwtYmJZYjdyNzVKZXpPU005RlhFVDZPWXNUVWdIRkZ3eFlUbG…

Google News ue, 07 Jul 2026

Charles River Laboratories International Stock Surges 27%, With A 9-Day Winning Spree - Trefis

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNS1VtODloN29pcjNlOWQ1WDVtY3h4ajBWSUMtMGhzVHJKQVRDaV9uYVp2SmhkY0RSMFc2dTl5LTRPU3lqTWRkRklKUEZwZ3VZekRiZDlRNWNHcWlHbWRjbkVOeFRHc2RtS3B1YTFjQ2U5M1o5aFJMVE5BbHRKY21CeFg1N2NwSVBZbmdTQk…

CRL — Frequently Asked Questions

What is the current share price of Charles River Laboratories International, Inc. (CRL)?

As of 2026-07-15 16:51 PDT, Charles River Laboratories International, Inc. (CRL) trades at $228.22 on NYSE. Its 52-week range is $145.57 to $233.60.

What is the market capitalisation of CRL?

Charles River Laboratories International, Inc. (CRL) has a market capitalisation of $10.99B on NYSE.

What is the P/E ratio of CRL?

CRL trades at a trailing price-to-earnings (P/E) ratio of -61.35. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 3.79.

What is the return on equity (ROE) of CRL?

CRL has a return on equity (ROE) of -5.87%. Its return on capital employed (ROCE) is 0.42%.

Is CRL a good stock to buy?

This page provides a data-driven analysis of Charles River Laboratories International, Inc. (CRL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space